In a moment that mirrors a broader reckoning across international sport, the Women's Tennis Association has chosen genetic certainty over hormonal measurement as its standard for eligibility — requiring a one-time SRY gene test of all players beginning in 2026. The decision joins a growing alignment among governing bodies, from World Athletics to the IOC, who are reaching for biological definitions in a debate that has long resisted resolution. No transgender women are currently competing professionally in tennis, yet the policy carries the full weight of a question humanity has not yet answer
WTA Mandates One-Time Gene Test for Women's Tennis Eligibility
A one-time genetic test replaces years of hormone monitoring
Mark
Why did the WTA feel it needed to change its eligibility rules now, when there are no transgender women currently competing in professional tennis?
Mimi
That's the question that hangs over this. The policy shift seems to reflect pressure from other sports bodies and perhaps a desire to establish a clear standard before any case actually arises. It's preventive governance rather than responsive.
Mark
But a genetic test feels more invasive than checking testosterone levels. Why move in that direction?
Mimi
The WTA would argue it's more objective—a one-time test rather than ongoing monitoring. But you're right that it's a different kind of intrusion. It's asking players to submit biological material for a genetic marker, which carries its own privacy implications.
Mark
What do the players themselves think about this?
Mimi
We don't have widespread player statements yet. The WTA says it's conducting a "comprehensive player engagement program," which suggests they know this is contentious. Some players like Sabalenka have expressed fairness concerns; others like King see it as discriminatory. Most haven't weighed in publicly.
Mark
Is there actually scientific consensus that the SRY gene test answers the fairness question?
Mimi
Not really. The test identifies a genetic marker, but it doesn't measure athletic advantage. Critics of transgender inclusion argue that physical advantages from male puberty persist regardless of what a gene test shows. Advocates argue the test oversimplifies a complex biological and social question.
Mark
So both sides feel like they're being ignored?
Mimi
Exactly. The WTA is trying to find neutral ground by pointing to science, but science doesn't actually settle the underlying disagreement about what fairness means in sport.
Il Polso
- The WTA has replaced two years of testosterone monitoring with a single genetic test, a shift that redraws the boundary of who is recognized as eligible to compete in women's professional tennis.
- Transgender advocacy groups have condemned the move as biological determinism dressed in the language of fairness, warning that genetic screening sets a discriminatory precedent across all of sport.
- The policy lands in alignment with the IOC, World Athletics, and World Boxing, suggesting a consolidating institutional consensus that is outpacing the ethical debate it has not resolved.
- Legends of the sport are divided — Billie Jean King calls exclusion discrimination, while Aryna Sabalenka and Martina Navratilova argue that inclusion undermines competitive equity for cisgender women.
- With no transgender players currently on tour, the rule changes no one's immediate reality — but it reshapes the architecture of who may one day belong.
In a moment that mirrors a broader reckoning across international sport, the Women's Tennis Association has chosen genetic certainty over hormonal measurement as its standard for eligibility — requiring a one-time SRY gene test of all players beginning in 2026. The decision joins a growing alignment among governing bodies, from World Athletics to the IOC, who are reaching for biological definitions in a debate that has long resisted resolution. No transgender women are currently competing professionally in tennis, yet the policy carries the full weight of a question humanity has not yet answered: how do institutions hold both fairness and belonging at once.
The Women's Tennis Association has announced that all players seeking to compete professionally must undergo a one-time genetic screening for the SRY gene beginning in 2026. Administered through a cheek swab or blood draw and protected by confidentiality protocols, the test replaces the organization's previous framework, which had allowed transgender women to compete provided they maintained testosterone levels below a set threshold for two consecutive years.
The shift places the WTA alongside a growing coalition of governing bodies — World Athletics, World Boxing, and the International Olympic Committee — that have moved toward genetic markers as the basis for female category eligibility. The WTA framed the change as a clearer and more definitive standard, pledging to implement it with dignity and respect as part of a broader athlete engagement effort.
The policy arrives without an immediate target: no transgender women are currently known to be competing at any level of professional tennis. Yet it has reopened a debate with deep roots in the sport. Billie Jean King, whose 1973 "Battle of the Sexes" made her a civil rights symbol, sees the exclusion of transgender athletes as discrimination. Aryna Sabalenka, the world number one, has argued the opposite — that inclusion is unfair to cisgender women. The sport's own history includes Renée Richards, who competed on the women's tour in the late 1970s and later coached Martina Navratilova, herself a prominent critic of transgender inclusion.
Transgender advocacy organizations argue that reducing eligibility to genetic markers is a form of biological determinism that fails to account for the full complexity of identity and fairness. Opponents of transgender inclusion counter that the physiological effects of male puberty persist beyond transition in ways hormone therapy cannot fully reverse. The WTA has staked its position — but whether a genetic test can settle what is, at its core, a philosophical dispute remains an open question.
The Women's Tennis Association announced a significant shift in how it will determine eligibility for its professional tour. Starting Tuesday, every player seeking to compete will undergo a one-time genetic screening for the SRY gene—a marker used to establish biological sex. The test can be administered through a simple cheek swab or blood draw, and the WTA says it will begin screening players in 2026, with all results handled under strict confidentiality protocols.
This represents a marked departure from the organization's previous approach. Until now, the WTA had permitted transgender women to compete if they declared their gender identity as female and then maintained testosterone levels below a specified threshold for two consecutive years before entering tournaments. That framework, rooted in hormone-based eligibility criteria, has given way to a genetic test that the WTA argues provides a clearer, more definitive standard.
The timing of the policy change reflects a broader movement across international sports governance. World Athletics and World Boxing have already adopted similar genetic screening measures. In March, the International Olympic Committee announced that only athletes whose biological female status has been confirmed through a one-time genetic test would be eligible to compete in female category events at future Olympic Games. The WTA's decision aligns the sport with this emerging consensus among major governing bodies.
Currently, there are no known transgender women competing at any level of professional tennis, which means the policy will not immediately affect any active player on the tour. The WTA emphasized in its statement that it recognizes the sensitivity of the issue and pledged to implement the new requirements with dignity and respect, framing the change as part of a broader engagement program with its athletes.
The policy has reignited a longstanding debate within sports and beyond. Billie Jean King, the 12-time Grand Slam champion who became a civil rights icon after her 1973 "battle of the sexes" victory, views the exclusion of transgender athletes as a form of discrimination. Aryna Sabalenka, the current world number one, has expressed concern that allowing transgender competitors would be unfair to cisgender women. The sport's history includes Renee Richards, a transgender player who competed on the professional women's tour from 1977 to 1981 and later coached Martina Navratilova, herself an 18-time Grand Slam winner and vocal opponent of transgender inclusion in athletics.
Transgender advocacy organizations have been swift to condemn genetic screening policies across sports, arguing that such tests constitute discrimination against transgender people. They contend that eligibility frameworks rooted in genetic markers reduce complex questions of fairness and inclusion to biological determinism. Critics of transgender inclusion, by contrast, maintain that the physical advantages conferred by male puberty—including musculoskeletal development—persist even after transition and cannot be fully mitigated through hormone therapy alone.
The WTA's move signals that professional tennis has chosen to prioritize what it views as a scientifically objective standard over the hormone-monitoring system it previously employed. Whether this approach will settle the underlying tensions in sports governance, or simply shift the terms of the debate, remains to be seen.
Citazioni salienti
Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene, with all appropriate confidentiality and data privacy safeguards.— WTA spokesperson
The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way.— WTA statement
Vuoi la storia completa?
Leggi l'originale su Al Jazeera ↗
Sports